- Home
- CNTA vs CLVT Comparison
CNTA vs CLVT Comparison
Compare CNTA & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- CLVT
- Stock Information
- Founded
- CNTA 2020
- CLVT 2016
- Country
- CNTA United Kingdom
- CLVT United Kingdom
- Employees
- CNTA N/A
- CLVT N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- CLVT EDP Services
- Sector
- CNTA Health Care
- CLVT Technology
- Exchange
- CNTA Nasdaq
- CLVT Nasdaq
- Market Cap
- CNTA 2.3B
- CLVT 2.5B
- IPO Year
- CNTA 2021
- CLVT N/A
- Fundamental
- Price
- CNTA $22.52
- CLVT $3.48
- Analyst Decision
- CNTA Strong Buy
- CLVT Hold
- Analyst Count
- CNTA 9
- CLVT 5
- Target Price
- CNTA $31.75
- CLVT $4.83
- AVG Volume (30 Days)
- CNTA 859.3K
- CLVT 3.8M
- Earning Date
- CNTA 11-12-2025
- CLVT 10-29-2025
- Dividend Yield
- CNTA N/A
- CLVT N/A
- EPS Growth
- CNTA N/A
- CLVT N/A
- EPS
- CNTA N/A
- CLVT N/A
- Revenue
- CNTA $15,000,000.00
- CLVT $2,501,200,000.00
- Revenue This Year
- CNTA N/A
- CLVT N/A
- Revenue Next Year
- CNTA N/A
- CLVT N/A
- P/E Ratio
- CNTA N/A
- CLVT N/A
- Revenue Growth
- CNTA 118.88
- CLVT N/A
- 52 Week Low
- CNTA $9.60
- CLVT $3.04
- 52 Week High
- CNTA $25.42
- CLVT $6.70
- Technical
- Relative Strength Index (RSI)
- CNTA 34.27
- CLVT 43.64
- Support Level
- CNTA $23.45
- CLVT $3.20
- Resistance Level
- CNTA $25.35
- CLVT $3.73
- Average True Range (ATR)
- CNTA 1.23
- CLVT 0.17
- MACD
- CNTA -0.33
- CLVT 0.00
- Stochastic Oscillator
- CNTA 37.17
- CLVT 49.19
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.